分析噻托溴铵联合沙美特罗/氟替卡松在慢性阻塞性肺疾病治疗中的临床价值
|
摘要
目的探讨治疗慢性阻塞性肺疾病中使用噻托溴铵联合沙美特罗/氟替卡松的临床效果。方法随机抽取在周口市儿童医院接受治疗的100例慢性阻塞性肺疾病患者进行观察并分为两组,采取不同药物进行治疗。对照组:使用常规的方法联合沙美特罗/氟替卡松进行治疗;观察组:使用噻托溴铵联合沙美特罗/氟替卡松进行治疗,比较其治疗后效果。结果两组经治疗后的效果对比,对照组的总有效率、肺功能指标、动脉血气指标相比于观察组的总有效率、肺功能指标、动脉血气指标的效果较差,差异有统计学意义。结论治疗慢性阻塞性肺疾病采用噻托溴铵联合沙美特罗/氟替卡松药物的效果显著,不仅可以提高治疗效果、生活质量,同时还能改善肺功能指标,临床具有重要价值。
Objective To explore clinical effect of the treatment of chronic obstructive pulmonary disease using tiotropium bromide combined with fluticasone propionate/Shah Mette Lo. Methods Randomly selecting 100 patients with chronic obstructive pulmonary disease in the hospital,and dividing them into two groups,taking different drugs for treatment. In control group,50 patients received conventional methods combined with Shah Mette Lo/fluticasone treatment. In observation group,50 cases of patients received tiotropium bromide combined with Shah Mette Lo/fluticasone treatment. The effect after treatment was compared between the two groups. Results Treatment effects of two groups were compared. The total efficiency,pulmonary function index,total effective arterial blood gas index of the control group were worse compared with the observation group. The difference was statistically significant.Conclusion Tiotropium in treatment of chronic obstructive pulmonary disease of tiotropium bromide combined Shah Mette Lo/fluticasone drug has significant effect. It not only can improve the therapeutic effect,but also can improve quality of life. At the same time it can improve the pulmonary function. So it has important clinical value.
Objective To explore clinical effect of the treatment of chronic obstructive pulmonary disease using tiotropium bromide combined with fluticasone propionate/Shah Mette Lo. Methods Randomly selecting 100 patients with chronic obstructive pulmonary disease in the hospital,and dividing them into two groups,taking different drugs for treatment. In control group,50 patients received conventional methods combined with Shah Mette Lo/fluticasone treatment. In observation group,50 cases of patients received tiotropium bromide combined with Shah Mette Lo/fluticasone treatment. The effect after treatment was compared between the two groups. Results Treatment effects of two groups were compared. The total efficiency,pulmonary function index,total effective arterial blood gas index of the control group were worse compared with the observation group. The difference was statistically significant.Conclusion Tiotropium in treatment of chronic obstructive pulmonary disease of tiotropium bromide combined Shah Mette Lo/fluticasone drug has significant effect. It not only can improve the therapeutic effect,but also can improve quality of life. At the same time it can improve the pulmonary function. So it has important clinical value.
引文
[1]许迎辉,李响,韩玉英.噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对慢性阻塞性肺疾病患者肺功能的影响[J].中国医药导报,2016,13(3):146-149.
[2]简亚梅,张少兴,彭永林.沙美特罗/丙酸氟替卡松联合盐酸氨溴索对慢性阻塞性肺疾病患者肺功能和血气指标的影响[J].中国当代医药,2015,22(2):88-90.
[3]翟见喜.吸入噻托溴胺联合沙美特罗替卡松对稳定期慢性阻塞性肺疾病患者肺功能及生活质量的影响[J].社区医学杂志,2015,13(4):17-18.
[4]滕鸿,李岱.噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对COPD患者肺功能的影响[J].浙江实用医学,2015,20(3):185-187.
[5]忠富,何小花,王玲霞.噻托溴铵吸入剂联合沙美特罗替卡松粉吸入剂对中重度慢性阻塞性肺疾病患者稳定期的肺功能及预后的影响[J].中国临床药理学杂志,2017,33(12):1075-1078.
[6]张慎峰.噻托溴铵与舒利迭联合与单用舒利迭对慢性阻塞性肺疾病肺功能的影响[J].黑龙江医学,2010,34(12):937-939.
[7]李朝霞.噻托溴铵和沙美特罗/丙酸氟替卡松联合治疗稳定期慢性阻塞性肺疾病患者的疗效观察[J].医药论坛杂志,2015,36(7):156-157.
[8]VESTBO J,HURD S S,AGUSTI A G,et al.Global strategy for the di-agnosis management,and prevention of chronic obstructive pul-monary disease:GOLD executive summary[J].American Journal of Respiratory and Critical Care Medicine,2013,187(4):347-365.
[2]简亚梅,张少兴,彭永林.沙美特罗/丙酸氟替卡松联合盐酸氨溴索对慢性阻塞性肺疾病患者肺功能和血气指标的影响[J].中国当代医药,2015,22(2):88-90.
[3]翟见喜.吸入噻托溴胺联合沙美特罗替卡松对稳定期慢性阻塞性肺疾病患者肺功能及生活质量的影响[J].社区医学杂志,2015,13(4):17-18.
[4]滕鸿,李岱.噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对COPD患者肺功能的影响[J].浙江实用医学,2015,20(3):185-187.
[5]忠富,何小花,王玲霞.噻托溴铵吸入剂联合沙美特罗替卡松粉吸入剂对中重度慢性阻塞性肺疾病患者稳定期的肺功能及预后的影响[J].中国临床药理学杂志,2017,33(12):1075-1078.
[6]张慎峰.噻托溴铵与舒利迭联合与单用舒利迭对慢性阻塞性肺疾病肺功能的影响[J].黑龙江医学,2010,34(12):937-939.
[7]李朝霞.噻托溴铵和沙美特罗/丙酸氟替卡松联合治疗稳定期慢性阻塞性肺疾病患者的疗效观察[J].医药论坛杂志,2015,36(7):156-157.
[8]VESTBO J,HURD S S,AGUSTI A G,et al.Global strategy for the di-agnosis management,and prevention of chronic obstructive pul-monary disease:GOLD executive summary[J].American Journal of Respiratory and Critical Care Medicine,2013,187(4):347-365.